Showing items 1 - 3 of 3

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

- Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil

A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

- Hertzberg, Mark, Matthews, Jane Palfrey, Abdi, Ehtesham, Green, Michael, Bonaventura, Anthony, Marlton, Paula, Cannell, Paul, Wolf, Max, Stone, Janey Malka, Dubosq, Ming-Celine, Grigg, Andrew, Ellis, David, Benson, Warwick, Browett, Peter, Horvath, Noemi, Januszewicz, Henry

Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

- Goldstein, David, Gainford, M Corona, Miller, Danielle, Shannon, Jenny, Brown, Chris, Tebbutt, Niall, Ackland, Stephen P., van Hazel, Guy, Jefford, Michael, Abdi, Ehtesham, Selva-Nayagam, Sid, Gebski, Val

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit